Transasia Bio-Medicals’ international hematology range backed by European R&D is now in Uttar Pradesh; eyes 300 crores in FY2019-20 from hematology in Indian market
Priced 25% below comparable options, the new range will make world-class diagnostics affordable for the masses in Uttar Pradesh
Lucknow April 20, 2019: Transasia Bio-Medicals Ltd., India's No. 1 In-vitro Diagnostic (IVD) Company and among the leading global players focused on emerging markets, today as part of its 40th anniversary celebration announced that its international hematology range, is now available in Uttar Pradesh. Backed by European R&D, the 3-Part Differential Analyzer (3PDA) to 5-Part Differential Analyzer (5PDA) fully automated haematology analyzers, reagents and controls include a number of features to help institutions, clinicians and lab technologists offer accurate diagnosis. Manufactured by Erba Lachema (100% owned subsidiary of Transasia) in Europe, the H 360, H 560 and ELite 580 hematology analyzers are widely used in the European and global market. Hematology analyzers are extensively used in patient and research settings to count and characterize blood cells for disease detection and monitoring. Basic analyzers return a complete blood count (CBC) with a three-part differential white blood cell (WBC) count. Sophisticated analyzers measure cell morphology and can detect small cell populations to diagnose rare blood conditions.
In addition to the routine parameters, the new hematology range offers additional parameters such as P-LCR, P-LCC, that aid in enumeration of large or commonly known as ‘giant’ platelets. These parameters can be useful in differentiating conditions such as thrombocytosis (high platelet count) and thrombocytopenia (low platelet count), amongst others.
The instruments thus become particularly relevant for Lucknow, since it draws a lot of rural population especially from eastern Uttar Pradesh, where large platelets are prevalently seen in the blood samples.
Addressing the media, Suresh Vazirani, Chairman & Managing Director, Transasia Bio-Medicals Ltd., said, “In the last 2-3 years, Lucknow has witnessed a fast paced growth in the healthcare facilities and infrastructural development. In addition to some of the oldest, most reputed and established medical institutes such as the King George Medical University (KGMU) and Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGI), the city of Nawaabs will soon be home to big corporate hospitals such as Medanta Medicity. Lucknow thus becomes a preferred hub to cater to the healthcare needs of the entire spectrum of population and host of medical conditions across specialities. Moreover, the city attracts a lot of patients from the nearby areas who need not travel all the
way to New Delhi for treatment. For Transasia, it thus offers a great opportunity to ensure that our instruments can aid in early and accurate diagnosis.”
India ranks 145th among 176 countries on the quality and accessibility of healthcare parameter. Limited access to quality medical infrastructure, including skilled manpower and technologies have been the pain points of over 70% of Indians who live in smaller towns and rural areas. Transasia has been focusing on indigenous development & technology adoption which facilitates affordable diagnostics through domestic manufacturing.
Talking about the newly launched range, Dr. Dimitris Giantzoudis, Global Product Manager - Erba Group, UK, said, “Accepted world-over for their quality, precision and ease-of-operation, the Erba range of hematology products will increase the adoption of automated hematology testing among Indian diagnostic labs.”
Dr. Preet Kaur, M.D., Business Unit Head - Biochemistry,Transasia further stated, “The range provides holistic solutions for clinical testing in general and targeted diagnostics which is an added advantage for pediatric and geriatric population. Other unique features include flagging of abnormal samples, RFID, large colored LCD touch screen, customizable reporting formats, ability to connect to a Laboratory Information System (LIS) for result output and ready-to-use reagents that are cyanide free and environment-friendly. By addressing many challenges that labs and pathologists face, Transasia is helping healthcare professionals (HCPs) focus on giving patients the best possible care.”
Added Suresh Vazirani, “As per industry reports in 2018, India's medical devices industry is pegged at a $5.2 billion (Rs. 35,097.40 crore), most of which is imported. It is players like Transasia who are at the forefront of changing it and driving Make in India.”
About Transasia Bio-Medicals Ltd.: Founded in 1979, Transasia Bio-Medicals Ltd., India’s Leading In-vitro Diagnostic Company offers products and solutions in Biochemistry, Hematology, Coagulation, ESR, Immunology, Urinalysis, Critical Care, Diabetes Management, Microbiology and Molecular Diagnostics. Transasia provides doctors and patients with reliable, affordable and innovative Medical Diagnostic Systems, with an impressive install base of above 65,000 equipment across India. It has a vast network of the more than 250 service engineers, 400+ sales and marketing team, 23 zonal offices and 350+ distributors. It is the first Indian company to manufacture and export blood analyzers and reagents, in the 1990s. Today, Transasia’s indigenous research has resulted in development of state of the art, ‘Make in India’ products and technologies, enabling its products to be
among the best in the world. All along its journey spanning more than four decades, Transasia has been recognized for its commitment to healthcare. It has been conferred ‘The Economic Times Best Brands 2019’ award, ‘India Medical Device - Export Company of the Year’ and the ‘Global Growth Company-2014’ award by the World Economic Forum amongst many others. Headquartered in Mumbai, Transasia is a part of the global Transasia-Erba group. The group has spread its footprint across USA, UK, Germany, Czech Republic, France, Italy, Russia and Turkey through various acquisitions. Transasia-Erba Group’s production sites in India, Czech Republic and USA and R&D centres in France, UK, India and Czech Republic form a hub for indigenous manufacturing of world class deliverables. Today, the group serves millions across 100 countries. For further information, kindly visit www.erbamannheim.com
For editorial queries only contact: Anurag David – firstname.lastname@example.org / 9322501136